[go: up one dir, main page]

EP4565195A1 - Compositions cosmétiques modulant la lumière et leurs utilisations - Google Patents

Compositions cosmétiques modulant la lumière et leurs utilisations

Info

Publication number
EP4565195A1
EP4565195A1 EP23761296.5A EP23761296A EP4565195A1 EP 4565195 A1 EP4565195 A1 EP 4565195A1 EP 23761296 A EP23761296 A EP 23761296A EP 4565195 A1 EP4565195 A1 EP 4565195A1
Authority
EP
European Patent Office
Prior art keywords
light
modulating
cosmetic composition
composition
range
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23761296.5A
Other languages
German (de)
English (en)
Inventor
Audrey MANIERE
Julie LEIGNADIER
Joan ATTIA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lucas Meyer Cosmetics SAS
Original Assignee
Lucas Meyer Cosmetics SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lucas Meyer Cosmetics SAS filed Critical Lucas Meyer Cosmetics SAS
Publication of EP4565195A1 publication Critical patent/EP4565195A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02—Preparations containing skin colorants, e.g. pigments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q3/00—Manicure or pedicure preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/26—Optical properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/42—Colour properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/42—Colour properties
    • A61K2800/43—Pigments; Dyes
    • A61K2800/434—Luminescent, Fluorescent; Optical brighteners; Photosensitizers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • cosmetic compositions capable of modulating light emitted from non- uniform light-emitting sources to balance the light received, e.g., irradiance, on a target tissue, and consumer products containing light-modulating cosmetic compositions. Also provided are methods of making and using light-modulating cosmetic compositions and consumer products.
  • Typical strategies for protecting against the negative effects of non-uniform light-emitting sources attenuate the emitted blue light. However, these strategies do not modulate the light emitted from non-uniform light-emitting source to generate a balanced irradiance profile capable of producing a beneficial result. There is thus a need for new strategies to convert potentially harmful light emitted from non-uniform light sources to more balanced light, e.g., white light, capable of delivering beneficial effects.
  • compositions and methods that address these and other needs in the art.
  • a light-modulating cosmetic composition including one or more photoluminescent compounds, wherein the composition modulates an irradiance of a non-uniform light-emitting source on a target tissue.
  • a consumer product including a light-modulating cosmetic composition described herein.
  • the consumer product is a cream, a lotion, a gel, a foam, a paste, a salve, a balm, a varnish, or an ointment.
  • a method of modulating an irradiance from a non-uniform lightemitting source on a target tissue including topically applying a light-modulating cosmetic composition or a consumer product described herein to a target tissue.
  • a method of reducing or preventing photodamage to a target tissue from a light emitted from a non-uniform light-emitting source including topically applying a lightmodulating cosmetic composition or a consumer product described herein to a target tissue.
  • a method of reducing or preventing aging of a target tissue from a light emitted from a non-uniform light-emitting source including topically applying a lightmodulating cosmetic composition or a consumer product described herein to a target tissue.
  • a method of reducing or preventing oxidative stress of a target tissue from a light emitted from a non-uniform light-emitting source including topically applying a light-modulating cosmetic composition or a consumer product described herein to a target tissue.
  • a method of modulating photoactivation of a chromophore in a target tissue by a light emitted from a non-uniform light-emitting source including topically applying a light-modulating cosmetic composition or a consumer product described herein to a target tissue.
  • a method of improving an appearance of a target tissue exposed to a light emitted from a non-uniform light-emitting source including topically applying a lightmodulating cosmetic composition or a consumer product described herein to a target tissue.
  • a method of improving a well-being of a subject exposed to a light emitted from a non-uniform light-emitting source including topically applying a light-modulating cosmetic composition or a consumer product described herein to a target tissue.
  • a method of making a consumer product including: (a) adding to a cosmetic base a light-modulating cosmetic composition described herein to form a mixture; and (b) stirring the mixture to achieve homogeneity.
  • the method includes emulsifying the mixture.
  • the method includes cooling the mixture.
  • the method includes adjusting the pH of the mixture.
  • kits comprising a light-modulating cosmetic composition as described herein and instructions for use.
  • FIG. 1 shows the coupled absorption and emission spectra of an exemplary Test Mix (see, Section V, Table El).
  • the emission spectrum was obtained by illuminating the exemplary Test Mix with a monochromatic light at 455 nm.
  • FIG. 2 shows the experimental design for assessing the light transforming effect of the exemplary Test Mix (see, Section V, Table El) when illuminated by a digital screen.
  • FIG. 3 shows an exemplary computer screen emission spectrum (30 cm).
  • FIGS. 4A-4B show the visible light modulation, determined by measuring irradiance, of an exemplary Test Mix (see, Section V, Table El) when illuminated by an exemplary computer screen (FIG. 4A) or an exemplary smartphone screen (FIG. 4B) at a distance of 30 cm under three environmental conditions: in darkness (Dark), under natural light (in the vicinity of a window; Natural Light), and in the presence of LED panels (Artificial Light).
  • FIGS. 4C-4E show hourly measured irradiance over 8 hours of the exemplary Test Mix and Placebo at 450 nm (FIG. 4C), 540 nm (FIG. 4D), and 600nm (FIG. 4E), when illuminated with an exemplary computer screen (30 cm) in a dark environment (no natural or artificial light).
  • FIG. 5 shows the average percentage ⁇ standard deviation of positive surface for 8-OHdG staining in skin explants that were untreated and not exposed to blue light, untreated and exposed condition to blue light, treated with Placebo and exposed to blue light, and treated with an exemplary Test Mix and exposed to blue light (see, Section V, Table El). The results were normalized to the untreated, unexposed reference condition. Statistical significance was assessed using the Mann-Whitney test (****p ⁇ 0.0001).
  • FIG. 6 shows the average percentage ⁇ standard deviation of Cytochrome c oxidase (CCO) activity in skin explants that were untreated and not exposed to blue light, untreated and exposed to blue light, treated with Placebo and exposed to blue light, and treated with an exemplary Test Mix and exposed to blue light (see, Section V, Table El). The results were normalized to the untreated, unexposed reference condition. Statistical significance was assessed using the Unpaired T test (***p ⁇ 0.0001, **p ⁇ 0.001, #p ⁇ 0.1).
  • FIG. 7A shows opsin 1SW expression, using immunostaining, in heathy human explants treated with an exemplary Text Mix (see, Section V, Table El), Placebo, or untreated, after 8 days of daily exposure to blue light.
  • FIG. 7B shows opsin 2 expression, using immunostaining, in heathy human explants treated with the exemplary Text Mix, Placebo, or untreated, after 8 days of daily exposure to blue light.
  • FIG. 7C shows the average percent ⁇ standard deviation of surface stained for opsin 1 SW and opsin 2 across treatment conditions. The values are normalized to 100% of the untreated, unexposed condition. Significance levels are set to *p ⁇ 0.05, **p ⁇ 0.01, ***p ⁇ 0.001 using the Mann-Whitney test.
  • FIG. 8A shows emission at 512 nm of an exemplary photoluminescent mixture (see, Example 1) in electromagnetized and non-electro magnetized water immediately following blue light exposure (482 nm).
  • FIG. 9A shows grayscale luminosity evaluated on several areas of the face (white outlines) before and after exposure to blue light (405 nm). Pictures illustrate the emission of light at 560 nm.
  • FIG. 9B shows average percentage ⁇ standard deviation of grayscale luminosity at 560 nm on defined areas immediately or 10 min after application of the exemplary Clinical Test Mix (see, Example 4, Table E4; dark bar) or Placebo (light bar) under exposure to blue light. The results were normalized to 100% of the area exposed to white light (Before). Statistical significance was assessed using a two-way Anova test (*p ⁇ 0.05; **p ⁇ 0.01).
  • FIGS. 10A-10F are bar graphs comparing various skin conditions in healthy volunteers who applied twice a day (morning and evening) either an exemplary Clinical Test Mix or Clinical Placebo (C. Test Mix or C. Placebo; see, Example 4, Table E4) and spent at least 6 hours daily in front of screens emitting blue light.
  • FIG. 10A shows the color of undereye dark circles as ITA°.
  • FIG. 10B shows anti-oxidative potential.
  • FIG. 10C shows skin glossiness.
  • FIG. 10D shows skin redness.
  • FIG. 10E shows the volume of wrinkles.
  • FIG. 10F shows skin roughness. All evaluations were conducted on day 28 of application and the values were normalized to 100% of the value at Day 0. Significance thresholds **p ⁇ 0.01, ***p ⁇ 0.001, ****p ⁇ 0.0001, *****p ⁇ 0.00001 using the Mann- Whitney test.
  • FIGS. 11 A- 11C compare measures of well-being in healthy volunteers who applied twice a day (morning and evening) either an exemplary Clinical Test Mix or Clinical Placebo (C. Test Mix or C. Placebo; see, Example 4, Table E4) and spent at least 6 hours daily in front of screens emitting blue light.
  • stress FIG. 11 A
  • energy of each chakra FIG. 11B
  • the global energy of chakra FIG. 11C
  • Significance thresholds ****p ⁇ 0.0001, *****p ⁇ 0.00001 using the Mann-Whitney test.
  • Sunlight is an energy source that enables various chemical reactions in the living world, and its absorption at varying wavelengths produces a wide range of molecules essential for biological function in plants and animals.
  • These biofluorescent animals absorb short-wavelength electromagnetic radiation and re-emit it at longer wavelengths, resulting in a bright fluorescent glow. This phenomenon, promoting communication, is based on several types of proteins, pigments, metabolites and chemical reactions.
  • Opsins are a large group of light-sensitive G protein-coupled receptors (GPCRs) whose activation triggers excitation wavelength-dependent signaling cascades. Thus, the expression of these skin photoreceptors reflects the wavelength to which the skin is exposed.
  • GPCRs G protein-coupled receptors
  • Electromagnetic radiation from the sun is the main source of visible light exposure on our skin, but not the only one.
  • Artificial light sources such as light-emitting diodes (LEDs), flash lamps, computers, televisions, and mobile phones, e.g., smartphones, are also sources of visible light.
  • white light Unlike the sun, which emits a balanced visible light spectrum called white light, artificial light sources, such as, but not limited, to digital screens from computers and smartphones, emit an unbalanced light with an intense peak in the blue light range. These and other sources of unbalanced light, are generally referred to herein as non-uniform light-emitting sources. While white light has beneficial effects on the skin and well-being of a subject (human subject), artificial light is associated with biological skin perturbation. Examples of such perturbations include, but are not limited to, skin wrinkles, dark undereye circles, oxidative stress, photodamage, photoaging, and rough, red, dull, and inflamed skin.
  • Non-uniform light-emitting sources may also impact, for example, a subject’s emotional stress levels, energy levels, and circadian rhythm, which can negatively affect their sense of well-being. Despite this, adults spend about 11 hours per day in front of a screen. In addition, many use other non-uniform light-emitting devices simultaneously (second screening).
  • Unbalanced visible light can be modulated by means of fluorescence mechanisms. Modulation strategies typically focus on absorbing harmful light to decrease the intensity of harmful light received by a subject. However, these strategies fail to transform the harmful light into a more balanced beneficial light by reemitting the energy at higher wavelengths.
  • the compositions e.g., light-modulating cosmetic compositions and consumer products containing such compositions, provided herein, use light emitted from non-uniform light-emitting sources, as an energy source and transform the non-uniform light into a more balanced mix of wavelengths, e.g., white light.
  • the compositions provided herein are advantageous in their ability to simultaneously protect the skin from harmful wavelengths and provide skin wellness benefits. Another advantage of the compositions provided herein is their commercial cosmetic usability. For example, the compositions provided herein may be used as cosmetic consumer products without the need to undergo therapeutic treatment.
  • light-modulating cosmetic compositions and consumer products containing light-modulating cosmetic compositions are also provided. Also provided are methods and uses of such light-modulating cosmetic compositions and consumer products. In aspects are provided methods of making consumer products containing light-modulating cosmetic compositions and kits containing light-modulating cosmetic compositions.
  • skin and grammatical variants thereof refer to any part of the skin of the human body, including the skin of the face, including the lips and eyelids, undereye skin, the neck, the scalp, and the skin of the hands.
  • the target tissue described herein is the skin at the level of the face, including the eye contour and the contour of the lips, and at the level of the neck.
  • Prevent”, “preventing”, “prevention”, “inhibit”, “inhibiting”, “inhibition” and grammatical variants thereof mean delaying or preventing the appearance of a sign, an effect, or a condition.
  • "Reducing”, “reduction”, and grammatical variants referred to in terms of the methods and uses described herein mean decreasing, attenuating, fading, correcting or slowing down the development of said sign, effect, or condition.
  • a reduction in any sign, effect, or condition described herein includes decreases of about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, inclusive of all values falling in between these percentages, in expression of the sign, effect, or condition prior to use of a composition described herein.
  • a reduction in any sign, effect, or condition described herein includes decreases of about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, inclusive of all values falling in between these percentages, in expression of the sign, effect, or condition relative to a subject having a sign, effect, or condition and not administered a composition described herein.
  • the sign, effect or condition is an adverse effect described herein.
  • a beneficial effect as described herein is the preventing or inhibiting of an adverse effect described herein.
  • the term “consumer” means both the user of the cosmetic composition or consumer product and the observer nearby or around the user.
  • cosmetic compositions having light-modulating activity which are generally referred to herein as light-modulating cosmetic compositions.
  • the light-modulating cosmetic compositions described herein modulate light from non-uniform light-emitting sources having emission profiles showing high intensity peaks in one or more wavelengths or bands of wavelengths known to have adverse effects on tissue, e.g., human tissue such as skin, hair, and nails, and/or subject well-being to convert the non-uniform light emitted from the source into a light with beneficial effects.
  • the adverse effect is or includes photodamagc, photoaging, aging, oxidative stress, redness, wrinkles, fine lines, dark undereye circles, emotional stress, and/or low chakra energy.
  • the adverse effect is or includes photodamage, photoaging, aging, oxidative stress, redness, wrinkles, fine lines, dark undereye circles, or roughness of a tissue exposed to a non-uniform light-emitting source.
  • the adverse effect is or includes emotional stress or low chakra energy.
  • a light-modulating cosmetic composition containing one or more photoluminescent compounds, for example as described in Section I-A below, that modulate an irradiance of a non-uniform light-emitting source on a target tissue.
  • the irradiance may be referred to as a spectral irradiance.
  • the target tissue is a tissue that is exposed to the non-uniform light source.
  • the subject is a human.
  • the target tissue is a human tissue.
  • the target tissue is skin, hair, and/or nails.
  • the target tissue is skin.
  • the target tissue is facial skin.
  • the target tissue is undereye skin.
  • the target tissue is hair, hr some embodiments, the target tissue is nails.
  • the light-modulating cosmetic composition modulates an intensity of light in one or more of an ultraviolet spectrum, a visible spectrum, or an infrared spectrum emitted by a non-uniform light-emitting source.
  • the modulation includes independently increasing, decreasing, or maintaining the intensity of the light.
  • the light-modulating cosmetic composition decreases high intensity emission wavelength peaks, increases emission wavelengths with intensities lower than the peak emission wavelengths, and maintains intensities of wavelengths with emission peaks between the high and low intensity emission wavelengths.
  • the light-modulating cosmetic composition independently modulates the intensity of different wavelengths from the non-uniform light-emitting source to produce an emission profile with balanced light.
  • the balanced light includes a mixture of wavelengths with equal or about equal intensities. In some embodiments, the balanced light includes a mixture of wavelengths where the emission profile does not have intense peaks. For example, the emission peak intensities differ by less than 20, 15, 10, 5, or 1%.
  • the modulation of intensity is determined by measuring irradiance (spectral irradiance).
  • the light-modulating cosmetic composition may modulate an emission profile of a non-uniform light-emitting source to produce a white light. In some embodiments, the light-modulating cosmetic composition modulates the irradiance of the non-uniform light-emitting source to produce a white light.
  • the lightmodulating cosmetic composition converts non-uniform light including peak emissions in wavelengths, or bands of wavelengths, with known adverse effects from a non-uniform lightemitting source into light having an emission profile with a beneficial effect.
  • the emission profile is or includes the visible light spectrum.
  • the beneficial effect is or includes reducing or preventing photodamage, photoaging, aging, oxidative stress, redness, wrinkles, fine lines, dark undereye circles, and roughness of a target tissue.
  • the beneficial effect is or includes maintaining or improving glossiness, brightness, or smoothness of a target tissue.
  • the target tissue is tissue exposed to non-uniform light-emitting sources.
  • the target tissue may be any tissue described herein.
  • the beneficial effect is or includes improving or maintaining the well-being of a subject, e.g., human subject.
  • the well-being is or includes decreasing emotional stress and/or increasing chakra energy.
  • Beneficial effects may be determined by comparing measures made prior to use of the lightmodulating cosmetic composition, or a consumer product containing the light-modulating cosmetic composition, for example consumer products described in Section I-B, and after use. For example, a comparison may be made after 1, 2, 3, 4, 5, 6 days, 1, 2, 3 weeks, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 months, or one or more years after use, for example continuous, intermittent, or cyclic use. Beneficial effects may also be determined by comparing against subjects exposed to identical conditions but who do not use a light-modulating cosmetic composition or consumer product described herein. Non-limiting methods of assessing beneficial effects are described in Sections II and V below.
  • a non-uniform light-emitting source includes light sources having emission profiles with high intensity peaks in one or more wavelengths or bands of wavelengths known to have adverse effects on tissue, e.g., human tissue such as skin, hair, and nails, and/or subject well-being. This type of emission profile may alternatively be referred to herein as unbalanced.
  • unbalanced is meant light that does not contain a mixture of wavelengths with equal or about equal intensities, and which includes high intensity peaks in one or more wavelengths or bands of wavelengths known to have adverse effects on tissue, c.g., human tissue such as skin, hair, and nails, and/or subject well-being.
  • tissue c.g., human tissue such as skin, hair, and nails, and/or subject well-being.
  • a non-uniform light-emitting source may be a light source that emits a single wavelength or narrow band of wavelengths (e.g., ⁇ 20, 10, 5 nm).
  • the single wavelength or narrow band of wavelengths is known to have adverse effects on tissue, e.g., human tissue such as skin, hair, and nails, and/or subject well-being.
  • the non-uniform light-emitting source is an artificial light source.
  • artificial light sources that are non-uniform light-emitting sources include, but are not limited to, computers such as desktop computers, laptop computers, and tablets; mobile phones (cell phones) such as smartphones; televisions; VR/AR devices; fluorescent lights; and LEDs, and components thereof, e.g., a screen, that emits non-uniform light.
  • the non- uniform light-emitting source is a computer, e.g., desktop computer, laptop computer, tablet.
  • the non-uniform light-emitting source is a tablet.
  • the non-uniform light-emitting source is a mobile phone. In some embodiments, the non-uniform light-emitting source is a mobile phone that is a smartphone. In some embodiments, the non- uniform light-emitting source is a smartphone. In some embodiments, the non-uniform lightemitting source is a television. In some embodiments, the component is a screen, e.g., computer screen, tablet screen, television screen, mobile phone screen. In some embodiments, the non- uniform light-emitting source is a light source that emits at least one non-uniform emission wavelength in the blue light spectrum. For example, the non-uniform light-emitting source is a light source having a peak emission in the blue light spectrum. In some embodiments, the non- uniform light-emitting source contains a peak emission in a wavelength in the blue light spectrum.
  • the light-modulating cosmetic compositions having the features described herein include photoluminescent compounds with the ability to modulate light intensities and irradiance, e.g., on a target tissue, from a non-uniform light-emitting source.
  • the photoluminescent compounds modulate the intensity of light in one or more of an ultraviolet spectrum, a visible spectrum, or an infrared spectrum emitted by a non-uniform light-emitting source.
  • the modulation includes independently increasing, decreasing, or maintaining the intensity of the light.
  • the modulation includes balancing light intensities from a non-uniform light-emitting source to produce a mixture of wavelengths with equal or about equal intensities.
  • the mixture of wavelengths with equal or about equal intensities is white light.
  • the photoluminescent compounds modulate the irradiance of the non-uniform light-emitting source to produce a white light, e.g., on a target tissue.
  • the light-modulating cosmetic composition includes one or more photoluminescent compounds, where the compounds modulate the same or different wavelengths of light.
  • each of the one or more compounds acts independently to increase, decrease, or maintain the intensity of a wavelength or band of wavelengths of light. For example, one photoluminescent compound may decrease the intensity of light while another compound may increase a different light intensity.
  • a photoluminescent compound in the light-modulating cosmetic composition may maintain a light intensity either by not interacting with the wavelength or preventing a loss of intensity.
  • two or more compounds modulate light of the same wavelength or band of wavelengths. For example, two or more compounds modulate blue light.
  • two or more compounds modulate light of different wavelengths or band of wavelengths. For example, one compound of the two or more compounds modulates blue light and a different compound modulates red light.
  • the light-modulating cosmetic composition includes at least 2 different photoluminescent compounds.
  • at least one compound has an absorption peak wavelength in a range of about 380 to about 500 nm.
  • each compound has at least one absorption peak wavelength in a range of about 380 to about 500 nm.
  • at least one compound has an emission peak wavelength in a range of about 500 to about 575 nm.
  • at least one other compound has an emission peak wavelength in a range of about 575 to about 780 nm.
  • at least one compound has an emission peak wavelength in a range of about 575 to about 780 nm.
  • the light-modulating cosmetic composition includes at least 3 different photoluminescent compounds.
  • the light-modulating cosmetic composition includes at least one photoluminescent compound having an emission peak wavelength in a range of about 400 to about 500 nm.
  • the photoluminescent compounds include organic pigments. In some embodiments, the photoluminescent compounds include inorganic pigments. In some embodiments, the photoluminescent compounds include organic pigments and inorganic pigments.
  • At least one compound having an emission peak wavelength in a range of about 500 to about 575 nm is selected from Octahydrocoumarin, Fluorescein, Eosin Y, Tartazine, 2h-l-benzopyran-2-one, Daphnetin, Coumarin, 7-Diethylamino-4-methylcoumarin, Quinoline, Scoparone, Curcurmine, and Naphthalimide.
  • at least one compound having an emission peak wavelength in a range of about 500 to about 575 nm is selected from Fluorescein and Eosin Y.
  • At least one other compound having an emission peak wavelength in a range of about 575 to about 780 nm is selected from Phloxine, Rhodamine B, Rhodamine 6G, Benzopyran, and Cyanine. In some embodiments, at least one other compound having an emission peak wavelength in a range of about 575 to about 780 nm is selected from Phloxine and Rhodamine B.
  • the light-modulating cosmetic composition includes at least one compound having an emission peak wavelength in a range of about 400 to about 500 nm selected from coumarin, aminocoumarin, and a disulphonic acid stilbene derivative. In some embodiments, the light-modulating cosmetic composition includes Fluorescein, Eosin Y, and Phloxine. In some embodiments, the light-modulating cosmetic composition includes Fluorescein, Eosin Y, CI47005, and Phloxine,
  • the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is at least about 0.001 , 0.005, 0.01 , 0.05, 0.1 , 0.5, 1 , 2, 3, 4, 5, 10, 15, 20, 30, 40, or 50% weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is at least about 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1, 2, 3, 4, 5, 10, 15 or 20% weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the lightmodulating cosmetic composition is at least about 0.001, 0.01, 0.1, 0.5, 1, 2, 3, 4, 5, 10 or 15% weight of the composition.
  • the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is at least about 0.001, 0.01, 0.1, 0.5, 1, 2, 3, 4, 5, or 10% weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is at least about 0.001, 0.01, 0.1, 0.5, 1, 2, 3, 4, or 5% weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in a range of about 0.001% to about 50% weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in a range of about 0.001% to about 40% weight of the composition.
  • the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in a range of about 0.001% to about 30% weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in a range of about 0.001% to about 20% weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in a range of about 0.001% to about 15% weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in a range of about 0.001% to about 10% weight of the composition.
  • the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in a range of about 0.001% to about 5% weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in a range of about 0.001% to about 2% weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in a range of about 0.001% to about 1% weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in a range of about 0.001% to about 0.5% weight of the composition.
  • the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in a range of about 0.001% to about 0.1% weight of the composition. In some embodiments, the total concentration of photoluminescent compounds in the light-modulating cosmetic composition is in a range of about 0.001% to about 0.01% weight of the composition.
  • the light-modulating cosmetic composition includes a first photoluminescent compound that comprises about 50% to about 100% of the total amount of photoluminescent compounds in the composition. In some embodiments, the light-modulating cosmetic composition includes a second photoluminescent compound that comprises about 0.0001% to about 15% of the total amount of photoluminescent compounds in the composition. In some embodiments, the light-modulating cosmetic composition includes a third photoluminescent compound that comprises about 0.0001 % to about 15% of the total amount of photoluminescent compounds in the composition. [0058] Tn some embodiments, the light-modulating cosmetic composition includes a first and a second photolumincsccnt compound at a ratio of 8:1.
  • the light-modulating cosmetic composition includes a first, a second, and a third photoluminescent compound at a ratio of 8:1:1. In some embodiments, the light-modulating cosmetic composition includes a first, a second, a third, and a fourth photoluminescent compound at a ratio of 5: 1:1:1.
  • the light-modulating cosmetic composition decreases an irradiance of blue light from the non-uniform light-emitting source.
  • the lightmodulating cosmetic composition emits an orange light.
  • the light-modulating cosmetic composition increases the irradiance of an orange light.
  • the lightmodulating cosmetic composition decreases an irradiance of blue light from the non-uniform lightemitting source and emits an orange light, e.g., increases the irradiance of the orange light.
  • the blue light is in the range of about 450 nm ⁇ about 50 nm.
  • the blue light is in the range of about 450 nm ⁇ about 25 nm. In some embodiments, the orange light is in the range of about 600 nm ⁇ about 50 nm. In some embodiments, the orange light is in the range of about 600 nm ⁇ about 25 nm. In some embodiments, the decrease in blue light irradiance is at least about 1, 2, 3, 4, 5, 10, 15, 20, 30, 40, or 50% compared to the unmodulated irradiance. In some embodiments, the decrease in blue light irradiance is in the range of about 1% to about 50% compared to the unmodulated irradiance.
  • the decrease in blue light irradiance is in the range of about 1% to about 40% compared to the unmodulated irradiance. In some embodiments, the decrease in blue light irradiance is in the range of about 1% to about 30% compared to the unmodulated irradiance. In some embodiments, the decrease in blue light irradiance is in the range of about 1% to about 20% compared to the unmodulated irradiance. In some embodiments, the decrease in blue light irradiance is in the range of about 1% to about 15% compared to the unmodulated irradiance.
  • the decrease in blue light irradiance is in the range of about 1% to about 10% compared to the unmodulated irradiance. In some embodiments, the decrease in blue light irradiance is in the range of about 1% to about 5% compared to the unmodulated irradiance.
  • the increase in orange light emission intensity is at least about 1, 2, 3, 4, 5, 10, 15, 20, 30, 40, or 50% compared to the unmodulated emission. Tn some embodiments, the increase in orange light emission intensity is at least about 1, 2, 3, 4, 5, 10, 15, 20, 30, or 40% compared to the unmodulated emission. In some embodiments, the increase in orange light emission intensity is at least about 1, 2, 3, 4, 5, 10, 15, 20, or 30% compared to the unmodulated emission.
  • the increase in orange light emission intensity is at least about 1, 2, 3, 4, 5, 10, 15, or 20% compared to the unmodulated emission.
  • the increase in orange light irradiance is in the range of about 1% to about 50% compared to the unmodulated irradiance.
  • the increase in orange light irradiance is in the range of about 1% to about 40% compared to the unmodulated irradiance.
  • the increase in orange light irradiance is in the range of about 1% to about 30% compared to the unmodulated irradiance.
  • the increase in orange light irradiance is in the range of about 1% to about 20% compared to the unmodulated irradiance.
  • the increase in orange light irradiance is in the range of about 1% to about 15% compared to the unmodulated irradiance. In some embodiments, the increase in orange light irradiance is in the range of about 1% to about 10% compared to the unmodulated irradiance. In some embodiments, the light-modulating cosmetic composition does not change (e.g., maintains) an irradiance of a wavelength at about 540 nm. For example, in some embodiments, the change in irradiance of a wavelength at about 540 nm is less than 5, 4, 3, 2, or 1 % compared to the unmodulated irradiance.
  • the light-modulating cosmetic composition includes one or more of glycerin, water (e.g., deionized water), a glycol derivative, a hydrogel, or other solvent or powder carrier acceptable for topical application.
  • the light-modulating cosmetic composition includes glycerin.
  • the light-modulating cosmetic composition includes glycerin and a hydrogel.
  • the light-modulating cosmetic composition includes one or more of glycerin, an acrylate (e.g., C10-30 alkyl acrylate cross-polymer), xanthum gum, or triglycerides (e.g., medium chain triglycerides).
  • the light-modulating cosmetic composition includes one or more of an emollient, a humectant, a gelling agent, an emulsifier, an oil, a wax, a preservative, a fragrance, an active ingredient, a pigment, a sunscreen, a colorant, a chelatant, or an antioxidant.
  • the light-modulating cosmetic composition includes a gelling agent.
  • the light-modulating cosmetic composition includes one or more of glyceryl stearate, PEG (e.g., PEG- 100 strearate), isononyl isononanoate, mineral oil, dimethicone, phenoxyethanol, methylparaben, ethylparaben, butylparaben, propylparaben, water, or sodium hydroxide.
  • PEG e.g., PEG- 100 strearate
  • isononyl isononanoate e.g., mineral oil, dimethicone, phenoxyethanol, methylparaben, ethylparaben, butylparaben, propylparaben, water, or sodium hydroxide.
  • the light-modulating cosmetic composition includes one or more of water, sodium phytate, alcohol, xanthan gum, C12-C16 alcohols, hydrogenated lecithin, palmitic acid, isoamyl laurate, shorea stenoptera seed butter, diisopropyl adipate, shea butter cetyl esters, behenyl alcohol, butyrospermum parkii (shea) butter unsaponifiablcs, soybean glycerides, macadamia ternifolia seed oil, dimethicone, fragrance, helianthus annuus (sunflower) seed oil, tocopherol, phenoxyethanol or caprylyl glycol.
  • water sodium phytate
  • alcohol xanthan gum
  • C12-C16 alcohols hydrogenated lecithin
  • palmitic acid isoamyl laurate
  • shorea stenoptera seed butter diisopropyl adipate
  • shea butter cetyl esters shea butter cet
  • the light-modulating cosmetic composition includes one or more active agents with cosmetic effects.
  • An active ingredient with cosmetic effect, active agent with cosmetic effect, cosmetic agent, or active ingredient with cosmetic effect refers to a compound capable of exerting at least one cosmetic effect on the skin, the hair, and/or nails.
  • a cosmetic effect means any non-therapeutic effect aimed at modifying and/or improving the visual appearance and mechanical properties of the skin, hair, and/or nails, e.g., protecting them from external aggressions (sun, wind, humidity, dryness, chemicals), preventing and/or correcting phenomena related to their aging, or preventing or treating the effects caused by stress or fatigue, inflammation.
  • the light-modulating cosmetic composition exerts a cosmetic effect independent of the additional active agents that have cosmetic effects.
  • agents include, among others, anti-wrinkle agents, anti-aging agents, antioxidant agents, anti-inflammatory agents, anti-stress agents, moisturizing agents, soothing agents, anti-redness agents, decongestant agents, exfoliants or exfoliating agents, matting agents, seboregulating agents, lightening active ingredients, anti-stain active ingredients, anti-dark undereye circle or anti-undereye bag agents, anti-stress agents, anti-fatigue agents, anti-pollution active ingredients, tensor agents, filters and sunscreens, and combinations thereof.
  • the light-modulating cosmetic composition may include an active ingredient selected from an anti-wrinkle agent, an anti-redness agent, an antioxidant agent, a moisturizing active ingredient, a soothing agent, a seboregulating agent, an anti- stain or lightening agent, a tensor agent, an anti-pollution active ingredient, anti-dark undereye circle or anti-undereye bag agents, a filter or sunscreen, and combinations thereof.
  • an active ingredient selected from an anti-wrinkle agent, an anti-redness agent, an antioxidant agent, a moisturizing active ingredient, a soothing agent, a seboregulating agent, an anti- stain or lightening agent, a tensor agent, an anti-pollution active ingredient, anti-dark undereye circle or anti-undereye bag agents, a filter or sunscreen, and combinations thereof.
  • a non-limiting example of anti-pollution agents includes extracts of Chrysanthellum Indicum polysaccharides, e.g., from a fermentation medium of Alteromonas and salts of Nigari.
  • Non-limiting examples of anti-undereye bag agents includes extracts of Chrysantellum Indicum or sulfated polysaccharides of algae, in particular Ofcophyllum nodosum or Asparagopsis Armata.
  • moisturizing agents include urea, pidolic acid (PCA) and its derivatives in particular its salts such as arginine PCA, chitosan PCA, its salts of copper (Copper PCA), magnesium (magnesium PCA), sodium (sodium PCA) or zinc, ethylhexyl PCA, calcium gluconate, hyaluronic acid and its salts and other glycosaminoglycans, frucosis, glucose, isomaltose, lactose, trehalose, polydextrose, sucrose (Sucrose), maltitol, mannitol, sorbitol, xylitol and other carbohydrates and derivatives,
  • Non-limiting examples of anti-aging agents include ascorbic acid and its derivatives such as magnesium ascorbyl phosphate, glycosaminoglycans and their derivatives, Cyathea polysaccharides, collagen, flaxseed extracts (Linum usitatissimum), peptides such as Caprooyl- Tetrapeptide-3 and trifluoroacetyl tripeptide-2, extracts of Polygonum aviculare. extracts of brown algae, in particular Ascophyllum nodosum, extracts of fems, especially Cyathea cumingii.
  • Non-limiting examples of anti-stress agents include RosalityTM products (a combination of rose water and rose essential oil) and rose cistus extract, for example marketed under the brand name IBR-ChillTM.
  • Non-limiting examples of soothing agents include allantoin, extracts of aloe, birch (e.g. Betula alba), fireweed (Epilobium angustifolium), chestnut (e.g. Castenea sativa), blueberry (e.g. Centaurea cyanus), centella (e.g. Centella asiatica), horsetail (e.g. Equisetum arvense), fennel (e.g. Foeniculum vulgare ), witch hazel (e.g. Hamamelis virginiana), ivy (e.g. Hedera helix), habiscus sabdariffa, lily (e.g. Lilium candidum), mallow (e.g.
  • Malva sylvestris Malva sylvestris), lemon balm (e.g. Melissa officinalis), skullcap (e.g. Scutellaria baicalensis), mimosa (e.g. Mimosa tenuiflora), potentilla (e.g. Potentilla erecta), an extract of oligosaccharides or an oligosaccharide, e.g. flax, peptides such as palmitoyl tripeptide-8, extracts of polysaccharides, including extracts of exopolysaccharides from the fermentation medium of Alteromonas and combinations thereof.
  • lemon balm e.g. Melissa officinalis
  • skullcap e.g. Scutellaria baicalensis
  • mimosa e.g. Mimosa tenuiflora
  • potentilla e.g. Potentilla erecta
  • an extract of oligosaccharides or an oligosaccharide e.
  • Non-limiting examples of antioxidant agents include HMR (hydroxy methyl resorcinol), ascorbic acid and its derivatives, vitamin B9, histidine hydrochloride, or a fireweed extract (Epilobium augustifolium). Active ingredients with antioxidant and vitamin-like effect are usually used in a mass percentage of at least 1% of the total weight of the cosmetic composition.
  • Non-limiting examples of seboregulatory agents include flax lignans, rice powder, zinc gluconate, sarcosine, an extract of Cinnamomum zeylanicum bark, an extract of avocado, an extract of Backhousia citriodora and combinations thereof.
  • Non-limiting examples of anti-redness agents include saponins, flavonoids, ruscogenins, esculosides, and extracts containing them, for example extracts of Rus cus, as well as certain essential oils, for example lavender or rosemary.
  • Non-limiting examples of anti-stain agents include extracts such as licorice (Glycyrrhyza glabra), jackfruit extract (Artocarpus heterophyllus), Rumcx extract (R.occidentalis), plant extracts belonging to the genus citrus, resveratrol, peptides such as oligopep tide-68, nonapeptide- 1, kojic acid, magnesium ascorbyl phosphate and combinations thereof.
  • the light-modulating cosmetic composition is contained in a cream, a lotion, a gel, a foam, a paste, a salve, a balm, a varnish, or an ointment.
  • the total concentration of photoluminescent compounds contained in the cream, the lotion, the gel, the foam, the paste, the salve, the balm, the varnish, or the ointment is at least about 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, or 1% weight.
  • the total concentration of photoluminescent compounds contained in the cream, the lotion, the gel, the foam, the paste, the salve, the balm, the varnish, or the ointment is in a range of about 0.001% to about 1% weight. In some embodiments, the total concentration of photoluminescent compounds contained in the cream, the lotion, the gel, the foam, the paste, the salve, the balm, the varnish, or the ointment is in a range of about 0.001% to about 0.5% weight.
  • the total concentration of photoluminescent compounds contained in the cream, the lotion, the gel, the foam, the paste, the salve, the balm, the varnish, or the ointment is in a range of about 0.001 % to about 0.1% weight. In some embodiments, the total concentration of photoluminescent compounds contained in the cream, the lotion, the gel, the foam, the paste, the salve, the balm, the varnish, or the ointment is in a range of about 0.001% to about 0.05% weight.
  • the total concentration of photoluminescent compounds contained in the cream, the lotion, the gel, the foam, the paste, the salve, the balm, the varnish, or the ointment is in a range of about 0.001% to about 0.01% weight. In some embodiments, the total concentration of photoluminescent compounds contained in the cream, the lotion, the gel, the foam, the paste, the salve, the balm, the varnish, or the ointment is in a range of about 0.001% to about 0.005% weight. It is understood that the percent weight is with respect to the weight of the composition.
  • the light-modulating cosmetic composition modulates the irradiance of the non-uniform light-emitting source on the target tissue for at least about 1, 2, 3, 4, 5, 6, 7, 8, or more hours.
  • a consumer product may be a facial or body powder, a foundation, a make-up product, an oil (c.g., body oil, facial oil), a mousse, a cream, a wax, a balm (e.g., lip balm), a mask, a paste, a foam, a salve, a gel, a varnish, an ointment, a lotion (e.g., a body lotion, facial lotion), a spray, a personal care product, a nail care product, a baby care product, a non-aerosol body spray, a body milk, a body cream, a sunscreen lotion, a sunscreen spray, a sun block, a roll-on product, an aerosol product, a natural spray product, a hair care product, a fabric care product, and the like.
  • an oil c.g., body oil, facial oil
  • a mousse e.g., a cream, a wax, a balm (e.g., lip balm)
  • the consumer product is a cream, a lotion, a gel, a foam, a paste, a salve, a balm, a varnish, or an ointment.
  • the consumer product is a cream.
  • the cream is an emulsion.
  • the consumer product is a lotion.
  • the consumer product is a varnish.
  • the consumer product is a personal care product, a skin care product, a body care product, a hair care product, a make-up product, a nail care product, or a baby care product.
  • the consumer product is a skin care product.
  • the consumer product is a body care product.
  • the consumer product is a nail care product.
  • the consumer product is a baby care product.
  • the total concentration of photoluminescent compounds contained in the consumer product is at least about 0.001, 0.005, 0.01, 0.05, 0.1, or 0.5, or 1% weight. In some embodiments, the total concentration of photoluminescent compounds contained in the consumer product is in a range of about 0.001% to about 1% weight. In some embodiments, the total concentration of photoluminescent compounds contained in the consumer product is in a range of about 0.001 % to about 0.5% weight. In some embodiments, the total concentration of photolumincsccnt compounds contained in the consumer product is in a range of about 0.001% to about 0.1% weight.
  • the total concentration of photoluminescent compounds contained in the consumer product is in a range of about 0.001% to about 0.05% weight. In some embodiments, the total concentration of photoluminescent compounds contained in the consumer product is in a range of about 0.001% to about 0.01% weight. In some embodiments, the total concentration of photoluminescent compounds contained consumer product is in a range of about 0.001% to about 0.005% weight. It is understood that the percent weight is with respect to the weight of the consumer product.
  • the methods and uses provided herein include topical application of the light-modulating cosmetic composition or consumer product to provide a beneficial effect to a target tissue and/or well-being of a subject.
  • a method of modulating an irradiance from a non-uniform lightemitting source on a target tissue including topically applying a light-modulating cosmetic composition or consumer product described herein to a target tissue.
  • an aspect is provided a method of reducing or preventing photodamage to a target tissue from a light emitted from a non-uniform light-emitting source, including topically applying a lightmodulating cosmetic composition or a consumer product described herein to a target tissue.
  • the photodamage includes photo-oxidative stress.
  • the photodamage includes photoaging.
  • a method of reducing or preventing aging of a target tissue from a light emitted from a non-uniform light-emitting source including topically applying a lightmodulating cosmetic composition or a consumer product described herein to a target tissue.
  • a method of reducing or preventing oxidative stress of a target tissue from a light emitted from a non-uniform light-emitting source including topically applying a light-modulating cosmetic composition or a consumer product described herein to a target tissue.
  • a method of modulating photoactivation of a chromophore in a target tissue by a light emitted from a non-uniform light-emitting source including topically applying a light-modulating cosmetic composition or a consumer product described herein to a target tissue.
  • the chromophore is water.
  • the chromophore is an opsin.
  • the opsin is contained in a photoreceptor. In some embodiments, the photoreceptor is present in the target tissue. In some embodiments, the opsin is opsin 1SW. In some embodiments, the opsin is opsin 2. In some embodiments, the opsin is opsin 1SW and opsin 2. In some embodiments, the chromophore is a cytochrome C oxidase (CCO). In some embodiments, the CCO is contained in a mitochondrion.
  • CCO cytochrome C oxidase
  • modulating photoactivation of the chromophore includes increasing or decreasing photoactivation of the chromophore. In some embodiments, modulating photoactivation of the chromophore includes stimulating a biological response in the target tissue. In some embodiments, the biological response includes one or more of restoring or maintaining a level of activity, increasing a level of activity, or decreasing a level of activity. Restoring activity refers to reaching a level of activity observed prior to exposure, optionally repeated exposure, to a non-uniform light-emitting source. Maintaining a level of activity refers to holding a level of activity following an exposure, optionally repeated exposure, to a non-uniform light-emitting source.
  • Increasing a level of activity refers to increasing an activity level that would have been maintained or decreased in response to exposure, optionally repeated exposure, to a non-uniform light-emitting source. Decreasing a level of activity refers to decreasing an activity level that would have been maintained or increased in response to exposure, optionally repeated exposure, to a non- uniform light-emitting source.
  • an increase in activity includes increases of at least or about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, inclusive of all values falling in between these percentages, in expression of the activity prior to use of a composition described herein.
  • an increase in an activity includes increases of at least or about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, inclusive of all values falling in between these percentages, in expression of activity relative to activity in a subject not using a composition described herein and exposed to identical conditions.
  • a decrease in activity includes decreases of at least or about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, inclusive of all values falling in between these percentages, in expression of the activity prior to use of a composition described herein.
  • a decrease in an activity includes decreases of at least or about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, inclusive of all values falling in between these percentages, in expression of activity relative to activity in a subject not using a composition described herein and exposed to identical conditions.
  • maintaining an activity includes no more than about a 15% change in expression of the activity prior to use of a composition described herein.
  • maintaining an activity includes no more than about a 15% change in expression of activity relative to activity in a subject not using a composition described herein and exposed to identical conditions.
  • maintaining an activity includes no more than about a 10% change in expression of the activity prior to use of a composition described herein. In some embodiments, maintaining an activity includes no more than about a 10% change in expression of activity relative to activity in a subject not using a composition described herein and exposed to identical conditions. In some embodiments, maintaining an activity includes no more than about a 5% change in expression of the activity prior to use of a composition described herein. In some embodiments, maintaining an activity includes no more than about a 5% change in expression of activity relative to activity in a subject not using a composition described herein and exposed to identical conditions.
  • the biological response is a cellular communication activity. In some embodiments, the cellular communication activity is increased. In some embodiments, the biological response is a photoreceptor expression activity. In some embodiments, the photoreceptor expression activity is increased expression of opsin 2. In some embodiments, the photoreceptor expression activity is decreased expression of opsin 1SW. In some embodiments, the biological response is a mitochondrial activity. In some embodiments, the mitochondrial activity is maintained or restored. Methods of measuring biological activity of interest are known in the art and non-limiting examples of such methods contemplated herein are described in Section V.
  • a method of improving an appearance of a target tissue exposed to a light emitted from a non-uniform light-emitting source including topically applying a lightmodulating cosmetic composition or a consumer product described herein to a target tissue.
  • the improving includes reducing or preventing a roughness of the target tissue or maintaining the smoothness of the target tissue.
  • the improving includes reducing or preventing wrinkles or fine lines in the target tissue.
  • the target tissue is undereye skin and the improving includes reducing the appearance of dark circles in the target tissue.
  • the improving includes reducing or preventing a redness of the target tissue. Redness may be a sign of inflammation in tissue.
  • the improving includes reducing or preventing an inflammatory response in the target tissue.
  • the improving includes increasing or maintaining a glossiness and/or brightness of the target tissue. Maintaining refers to holding a level of activity or condition following an exposure or repeated exposure to a non-uniform light-emitting source as described above. Increasing refers to increasing an activity level or condition that would have been maintained or decreased in response to exposure to a non-uniform light-emitting source as described above.
  • a method of improving a well-being of a subject exposed a light emitted from a non-uniform light-emitting source including topically applying a light-modulating cosmetic composition or a consumer product described herein to a target tissue.
  • the improving comprises decreasing an emotional stress level, for example compared to a level of emotional stress recorded prior to the use or compared to a level of emotional stress that may be reached if use had not occurred.
  • the improving comprises increasing chakra energy, for example compared to a level of energy recorded prior to the use or compared to a level of energy that may be reached if use had not occurred.
  • Methods of assessing stress and chakra energy levels are known in the art, and non-limiting examples of such methods are described in Section V. Levels and measures for determining an increase, decrease, or maintenance are as described above.
  • the target tissue described herein may be any human tissue.
  • the target tissue is any tissue exposed to non-uniform light-emitting sources.
  • the target tissue is skin.
  • the target tissue is facial skin.
  • the target tissue is undereye skin.
  • the target tissue is hair.
  • the target tissue is nails.
  • the dose of light-modulating cosmetic composition or consumer product to be administered and the frequency of administration vary according to the desired cosmetic effect, the characteristics of the individual, such as sex, age, hair type, and skin type.
  • the light-modulating cosmetic composition or consumer product can be applied to the area to be treated once a day, twice a day (c.g., morning and night), for several consecutive weeks or even months, for example for at least 3, 6, 9 months.
  • the subject can apply a dose of 1 g to 2 g of cosmetic composition or consumer product to his face in the evening or morning and evening.
  • a method of making a consumer product including adding to a cosmetic base a light- modulating cosmetic composition described herein to form a mixture, and (b) stirring the mixture to achieve homogeneity.
  • the mixture is emulsified.
  • the mixture is cooled.
  • the mixture is pH adjusted.
  • the cosmetic base includes one or more of water, emollients, humectants, gelling agents, emulsifiers, oils, waxes, butter, surfactants, preservatives, fragrance, actives ingredients, pigments, sunscreens, colorants, chelatants, or antioxidants.
  • the method includes adding one or more of an anti-wrinkle agent, an anti-aging agent, an antioxidant agent, a moisturizing agent, a soothing agent, an anti-redness agent, a decongestant agent, an exfoliant or exfoliating agent, a matting agent, a seboregulating agent, a lightening active ingredient, an anti-stain active ingredient, an anti-dark undereye circles or an anti-undereye bags agent, an anti-stress agent, an anti-fatigue, an anti-pollution active ingredient, a tensor agent, a filter or sunscreen.
  • an anti-wrinkle agent an anti-aging agent, an antioxidant agent, a moisturizing agent, a soothing agent, an anti-redness agent, a decongestant agent, an exfoliant or exfoliating agent, a matting agent, a seboregulating agent, a lightening active ingredient, an anti-stain active ingredient, an anti-dark undereye circles or an anti-undereye bags agent, an anti-stress
  • kits including the light-modulating cosmetic compositions described herein which may further include instructions on methods of using the composition, such as uses described herein.
  • the kits described herein may also include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for performing any methods described herein.
  • a light-modulating cosmetic composition comprising one or more photoluminescent compounds, wherein the composition modulates an irradiance of a non-uniform light-emitting source on a target tissue.
  • composition modulates an intensity of light in one or more of an ultraviolet spectrum, a visible spectrum, or an infrared spectrum emitted by the non-uniform light-emitting source.
  • compositions comprising at least 2 different photoluminescent compounds, each compound having at least one absorption peak wavelength in a range of about 380 to about 500 nm, at least one compound having an emission peak wavelength in a range of about 500 to about 575 nm, and at least one other compound having an emission peak wavelength in a range of about 575 to about 780 nm.
  • compositions comprising at least one photoluminescent compound having an emission peak wavelength in a range of about 400 to about 500 nm.
  • - at least one compound having an emission peak wavelength in a range of about 500 to about 575 nm is selected from Octahydrocoumarin, Fluorescein, Eosin Y, Tartazine, 2h-l-benzopyran-2-one, Daphnetin, Coumarin, 7-Diethylamino-4-methylcoumarin, Quinoline, Scoparone, Curcurmine, and Naphthalimide; and/or - at least one other compound having an emission peak wavelength in a range of about 575 to about 780 nm is selected from Phloxine, Rhodamine B, Rhodamine 6G, Benzopyran, and Cyanine.
  • composition comprises at least one compound having an emission peak wavelength in a range of about 400 to about 500 nm selected from coumarin, aminocoumarin, and a disulphonic acid stilbene derivative.
  • composition comprises a first photoluminescent compound that comprises about 50% to about 100% of the total amount of photoluminescent compounds in the composition and a second photoluminescent compound that comprises about 0.0001% to about 15% of the total amount of photoluminescent compounds in the composition.
  • composition comprises a third photoluminescent compound that comprises about 0.0001% to about 15% of the total amount of photoluminescent compounds in the composition.
  • composition of any one of embodiments 1 to 13, wherein the composition comprises one or more of glycerin, water, a glycol derivative, a hydrogel, or other solvent or powder carrier acceptable for topical application.
  • compositions comprising one or more of an emollient, a humectant, a gelling agent, an emulsifiers, an oil, a wax, a preservative, a fragrance, an active ingredient, a pigment, a sunscreen, a colorant, a chelatant, or an antioxidant.
  • non-uniform light-emitting source is one or more of a computer, a tablet, a mobile phone, a television, a fluorescent light, a light emitting diode (LED), or any other digital device or artificial light source comprising a light source that emits non-uniform light, optionally wherein at least one non-uniform emission wavelength is in the blue light spectrum.
  • the non-uniform light-emitting source is one or more of a computer, a tablet, a mobile phone, a television, a fluorescent light, a light emitting diode (LED), or any other digital device or artificial light source comprising a light source that emits non-uniform light, optionally wherein at least one non-uniform emission wavelength is in the blue light spectrum.
  • a consumer product comprising a light-modulating cosmetic composition of any one of embodiments 1 to 21, wherein the consumer product is a cream, a lotion, a gel, a foam, a paste, a salve, a balm, a varnish, or an ointment.
  • a method of modulating an irradiance from a non-uniform light-emitting source on a target tissue comprising topically applying a light-modulating cosmetic composition of any one of embodiments 1 to 21 or a consumer product of any one of embodiments 22 to 24 to a target tissue.
  • a method of reducing or preventing photodamage to a target tissue from a light emitted from a non-uniform light-emitting source comprising topically applying a light-modulating cosmetic composition of any one of embodiments 1 to 21 or a consumer product of any one of embodiments 22 to 24 to a target tissue.
  • a method of reducing or preventing aging of a target tissue from a light emitted from a non- uniform light-emitting source comprising topically applying a light-modulating cosmetic composition of any one of embodiments 1 to 21 or a consumer product of any one of embodiments 22 to 24 to a target tissue.
  • a method of reducing or preventing oxidative stress of a target tissue from a light emitted from a non-uniform light-emitting source comprising topically applying a light-modulating cosmetic composition of any one of embodiments 1 to 21 or a consumer product of any one of embodiments 22 to 24 to a target tissue.
  • a method of modulating photoactivation of a chromophore in a target tissue by a light emitted from a non-uniform light-emitting source comprising topically applying a light-modulating cosmetic composition of any one of embodiments 1 to 21 or a consumer product of any one of embodiments 22 to 24 to a target tissue.
  • chromophore comprises one or more of water, an opsin, or a cytochrome C oxidase (CCO).
  • the modulating photoactivation of the chromophore comprises increasing or decreasing photoactivation of the chromophore.
  • the modulating photoactivation of the chromophore comprises stimulating a biological response in the target tissue, wherein the biological response comprises one or more of restoring or maintaining a level of activity, increasing a level of activity, or decreasing a level of activity.
  • the biological response comprises one or more of a cellular communication activity, a photoreceptor expression activity, or a mitochondrial activity.
  • a method of improving an appearance of a target tissue exposed to a light emitted from a non- uniform light-emitting source comprising topically applying a light-modulating cosmetic composition of any one of embodiments 1 to 21 or a consumer product of any one of embodiments 22 to 24 to a target tissue.
  • a method of improving a well-being of a subject exposed to a light emitted from a non-uniform light-emitting source comprising topically applying a light-modulating cosmetic composition of any one of embodiments 1 to 21 or a consumer product of any one of embodiments 22 to 24 to a target tissue.
  • the non-uniform light-emitting source is one or more of a computer, a tablet, a mobile phone, a television, a fluorescent light, a light emitting diode (LED), or any other digital device or artificial light source comprising a light source that emits non-uniform light, optionally wherein at least one non-uniform emission wavelength is in the blue light spectrum.
  • the non-uniform light-emitting source is one or more of a computer, a tablet, a mobile phone, a television, a fluorescent light, a light emitting diode (LED), or any other digital device or artificial light source comprising a light source that emits non-uniform light, optionally wherein at least one non-uniform emission wavelength is in the blue light spectrum.
  • a method of making a consumer product comprising: (a) adding to a cosmetic base a lightmodulating cosmetic composition of any one of embodiments 1 to 21 to form a mixture; (b) stirring the mixture to achieve homogeneity; (c) optionally emulsifying the mixture; (d) optionally cooling the mixture; and (e) optionally adjusting the pH of the mixture.
  • the cosmetic base comprises one or more of water, emollients, humectants, gelling agents, emulsifiers, oils, waxes, preservatives, fragrance, actives ingredients, pigments, sunscreens, colorants, chelatants, or antioxidants.
  • kits comprising a light-modulating cosmetic composition according to any one of embodiments 1 to 21 and instructions for use.
  • the absorption spectrum was recorded by means of a UV-Vis spectrophotometer Cary 5 E.
  • the emission spectrum (with excitation at 455 nm) was recorded with a Spectrofluorometer (Fluorolog FL-3).
  • the Test Mix exhibited fluorescence properties, absorbing light between 400 and 550 nm and reemitting at higher wavelengths. When exposed to a wavelength of 455 nm, the Test Mix converted the monochromatic light into a range of 500-600 nm, yielding an overall orange light emission.
  • illuminance (lux) measurements were completed according to the set-up shown in FIG. 2.
  • Test Mix or Placebo was spread at 2 mg/cm 2 on a transparent PVC foil placed at 30 cm from a computer screen or smartphone screen.
  • An illuminance meter (CL70 F Konica Minolta) was located immediately behind the PVC foil and measured the illuminance of the digital screen light as transmitted by the gel. This design mimics the average distance between the screen and the skin of the face when a person works in front of a computer.
  • nm 1 represents the radiant flux of light received by a surface. It is the power per unit area received on a defined surface at a given moment. For example, the S factor at 455 nm is equal to 0.2667. Therefore, a radiant flux of 1 W/m 2 at this wavelength corresponds to 0.2667 lux.
  • the computer screen emitted an irregular spectrum displaying 3 distinct peaks. As shown in FIG. 3, the main peak is situated at 450-455 nm, in mid-blue light range and corresponds to the absorption range of photoluminescent compounds. Two other peaks, with lower intensity, are positioned at 540 and 590 nm.
  • the Test Mix When illuminated by the computer screen at 30 cm, the Test Mix was able to decrease the irradiance at 450 nm up to -16% regardless of the light environment (FIG. 4A). At the same time, the Test Mix provided an increase of irradiance at 600 nm particularly under natural light and dark conditions (up to +7 %) (FIG. 4A). The impact on the intermediate wavelength 540 nm was negligible. Similar' results were observed when illuminated with a smartphone screen at 30 cm (FIG. 4B).
  • Table E2 Irradiance (W/m 2 ) at 450 nm, 540 nm, and 600 nm when illuminated by a computer screen at different distances (cm) under “classical office” conditions.
  • Table E3 Irradiance (W/m 2 ) at 450 nm, 540 nm, and 600 nm when illuminated by a smartphone screen at different distances (cm) under “classical office” conditions.
  • the duration of the photoluminescent compound mixture’s effect on irradiance was assessed by illuminating the Test Mix with a computer screen at 30 cm and measuring the irradiance at 450 nm, 540 nm, and 600 nm hourly for 8 hours. As shown in FIGS. 4C-4E, the measured irradiance varied about or below 10% for each wavelength, demonstrating the stability of the photoluminescent compounds effect.
  • a total of 30 human skin biopsies were obtained from a plastic surgery patient (Caucasian woman, 32 years old). Each explant was kept in survival medium for 8 days and irradiated every day for 3 hours with blue light from a Solarbox® device (59 W/m 2 at 455 nm) corresponding to a radiation dose of 63.75 J/cm 2 . Test Mix or Placebo (see. Table El of Example 1) was applied topically before irradiation, at day 0 (DO), DI, D4, and D6. An untreated, unexposed group and an untreated, exposed group served as controls. At D8, explants were fixed and directly frozen for 8-OHdG and opsins immunostaining.
  • 8-hydroxydesoxyguanosine (8-OHdG) is one of the predominant forms of free radical- induced oxidative lesions in humans. This stable oxidative modified DNA product reflects the degree of oxidative damage to DNA. DNA oxidation in explants was detected by labelling 8- OHdG using a monoclonal anti-8-OHdG antibody coupled with biotin and revealed by substrate of peroxidase.
  • mitochondrial membrane In cells, the main function of mitochondria is to generate most of the chemical energy needed to power cell’s biochemical reactions. Most part of this machinery is in the inner mitochondrial membrane and includes the four electron transfer chain complexes (complex I, II, ITT and TV), ATP synthase (complex V) ubiquinone and cytochrome c as electron carrier.
  • the complex IV or cytochrome c oxidase (CCO) is the terminal enzyme of the electron transport chain which is involved in reduction of cytochrome c to oxygen to make H2O and in activation of complex V activation to synthesize ATP.
  • the respiratory chain of mitochondrial contributes to ROS (reactive oxygen species) production within cells.
  • mitochondrial activities arc sensitive to light exposure since mitochondria contain photosensitive chromophore, such as CCO, that can be activated or inhibited by light in the visible range. Blue light exposure is known to increase the ROS production by a deregulation of CCO activity leading to skin damage.
  • CCO photosensitive chromophore
  • CCO cytochrome c oxidase
  • Opsin 1SW and opsin 2 receptors are expressed on the surface of the skin, and their expressions are sensitive to light excitation. These cutaneous photoreceptors are sensitive to the light absorbed by the skin and each opsin has a distinct absorption spectrum and signal transduction, and their expressions depend on the skin’s exposure to light. Epidermal expression of opsin 1SW and opsin 2 has been found to increase after exposure to wavelengths between 355 and 470 nm, and at 500nm.
  • water that comprises our intracellular and extracellular fluids.
  • the water is an interface, an environment, and a support of interaction between cell and biological field.
  • Water is therefore a living, dynamic, highly mobile, and able to transmit vital information to living cells.
  • the water Withing living organism, the water is structured due to the presence of electromagnetic field coming for electrical activity product by several different types of cells, including neurons, endocrine and muscle cells but also entities exhibited within the skin such as sweat gland.
  • Structured water refers to increases in the numbers of aggregated hydrogen and oxygen atoms that form a cluster comprising 2 to hundreds of water molecules and this structured water is some energy modulators due to this ability to transfer proton and electron. Indeed, structured water is described as a vector involved in the transmission of biological information.
  • Table E4 Gel-cream test compositions for clinical studies.
  • the volunteers divided in 2 groups, applied the Clinical Test Mix or Clinical Placebo (see, Example 4, Table E4) twice a day, morning and evening.
  • the color of the volunteers’ undereye dark circles was evaluated by measuring the ITA° parameter by using Visia-CR, the skin’s anti-oxidative potential was analyzed using a Comeofix®, the skin’s redness was evaluated by Visia-CR RBX®, the glossiness of skin was measured by spectrophotometer CM-700D, and the wrinkles volumes and roughness were assessed by prime 3D.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne des compositions cosmétiques capables de moduler la lumière émise par des sources électroluminescentes non uniformes pour équilibrer la lumière reçue, par exemple, l'éclairement énergétique, sur un tissu cible, et des produits de consommation contenant des compositions cosmétiques modulant la lumière. L'invention concerne également des procédés de fabrication et d'utilisation de compositions cosmétiques modulant la lumière et de produits de consommation.
EP23761296.5A 2022-08-03 2023-08-02 Compositions cosmétiques modulant la lumière et leurs utilisations Pending EP4565195A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263394751P 2022-08-03 2022-08-03
PCT/US2023/029282 WO2024030474A1 (fr) 2022-08-03 2023-08-02 Compositions cosmétiques modulant la lumière et leurs utilisations

Publications (1)

Publication Number Publication Date
EP4565195A1 true EP4565195A1 (fr) 2025-06-11

Family

ID=87801005

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23761296.5A Pending EP4565195A1 (fr) 2022-08-03 2023-08-02 Compositions cosmétiques modulant la lumière et leurs utilisations

Country Status (3)

Country Link
EP (1) EP4565195A1 (fr)
CN (1) CN119630383A (fr)
WO (1) WO2024030474A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5626839A (en) * 1994-11-08 1997-05-06 Scales-Medeiros; Virginia Light responsive self-tanning products and methods for use
WO2006011014A1 (fr) * 2004-07-16 2006-02-02 L'oreal Composition cosmetique contenant des particules photoluminescentes
US20100266989A1 (en) * 2006-11-09 2010-10-21 Klox Technologies Inc. Teeth whitening compositions and methods
WO2011112414A2 (fr) * 2010-03-12 2011-09-15 Lipo Chemicals Inc. Composé, composition, et procédé pour protéger la peau contre la lumière visible à énergie élevée
US20130281913A1 (en) * 2012-04-20 2013-10-24 Klox Technologies Inc. Biophotonic compositions and methods for providing biophotonic treatment

Also Published As

Publication number Publication date
WO2024030474A1 (fr) 2024-02-08
CN119630383A (zh) 2025-03-14

Similar Documents

Publication Publication Date Title
CN110302071A (zh) 蓝光防护化妆品组合物及其制备方法和包含有该组合物的化妆品
US10953237B2 (en) Methods of providing skin care using phototherapy
WO2020202764A1 (fr) Activateur cellulaire
CN103025333A (zh) 用于保护皮肤免受高能可见光损伤的化合物、组合物及方法
HK1208808A1 (en) Cosmetic biophotonic compositions
US9913785B2 (en) Topical chicory extract skin care composition providing broad spectrum sunscreen
CN108025195A (zh) 叶黄素对人类皮肤细胞系抗蓝光的防护作用
US10849844B2 (en) Formulations for treatment of skin and methods of making and using the same
US7892523B2 (en) Cosmetic process for the treatment of the skin with sun-protection products and sun-protection products combination
US9744381B2 (en) Topical compositions and methods for influencing electromagnetic radiation on cutaneous extracellular matrix protein production
KR101327943B1 (ko) 보석에서 유래하는 광물성 농축물을 기초로 한 조성물
US11413226B2 (en) Phyllosilicate compositions and uses thereof for skin cell regeneration
WO2024030474A1 (fr) Compositions cosmétiques modulant la lumière et leurs utilisations
CN113677367A (zh) 含有紫外线波长转换物质和有机系油相增稠剂的乳化组合物
Leevutinun et al. Clinical evaluation of Gac extract (Momordica cochinchinensis) in an antiwrinkle cream formulation
Cernasov The design and development of anti-aging formulations
CN109172423A (zh) 一种精华油组合物及其制备方法和应用
JP6666080B2 (ja) シワ改善方法、シワ改善機能向上方法、シワ改善用化粧料、シワ改善機能向上用化粧料、及びその使用、並びにシワ改善用化粧料の製造方法
ES2890299T3 (es) Uso de extracto de la fruta Hylocereus undatus como colorante fluorescente de la piel
US20120156147A1 (en) Cosmetic composition; skin treatment kit; method for treating oily or mixed skin or acned skin
US20230052667A1 (en) Agent for maintaining or enhancing collagen production ability
Kay et al. # 1 Dermatologist Recommended: A Clinician’s Guide to Self-Tanning
WO2021153771A1 (fr) Promoteur de production d'acide hyaluronique
Meunier Photodamage: Protection
WO2021153776A1 (fr) Inhibiteur de l'angiogenèse

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20250206

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Free format text: CASE NUMBER: UPC_APP_0566_4565195/2025

Effective date: 20250718

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)